Evidence Farming: Implications for Open Architecture

796 views
725 views

Published on

Presented by Ida Sim, Mobile Health 2011, May 5, 2011

Published in: Health & Medicine
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
796
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
24
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Evidence Farming: Implications for Open Architecture

  1. 1. !"#$%&%()*+,#&-./(0,12#*3#4&5(64+ 71%&(8+9#3%3:+% 0$*(;#,<(=><(?9> >#+%34+<(@%&3%+(64+(@2#&#*2(*&$(A+*&52*3#4&*2(0&64+,*3#5 B&#"%+5#3C(46(@*2#64+&#*(;*&()+*&#54 =*C(D<(EF.. .G#39(39*&H5(34(I#9(J+*"#3K(=><(B@(>*"#5(*&$(L*#9:*(>:*&<(@42:,M#*
  2. 2. I%19+*5#&-(N>4%5(#3(G4+HOP(Complexes of) Outcome Exposures strength of association? Increased Text4Baby individual breastfeeding population
  3. 3. @:++%&3(811+4*9%5/(I@A Asthma App ER visits at 1 year 50 people 100 people Usual Care ER visits at 1 year 50 people populationQ A%535(1+%51%#R%$(#&3%+"%&3#4&5(*&$(4:34,%5Q A4(4&R+,(*(9C1439%5#5(*3(39%(141:2*3#4&(2%"%2Q ;3+4&-(#&3%+&*2("*2#$#3CQ ?+4M2%,5/(524S(34(5%3T:1<(%U1%&5#"%<(594+3T3%+,<(2*H +%2%"*&%(34(39%(+%*2(S4+2$
  4. 4. @:++%&3(811+4*9%5/(>*3*(=#&#&- EHR Exposures Outcomes ? Apps populationQ !U145:+%5(*&$(4:34,%5(6+4,(*+%(1+4%55(5C53%,5Q A4(-%&%+*3%(9C1439%5%5(*3(39%(141:2*3#4&(2%"%2Q ?+4M2%,5/(2#,#3%$(34($*3*(422%3%$<(S%*H(#&3%+&*2 "*2#$#3C(V$*3*(&43(4,12%3%(4+(5C53%,*3#W
  5. 5. @:++%&3(811+4*9%5/ LT46T.(;3:$#%5 Asthma app Usual Care Asthma app peak flow peak flow Usual Care Asthma app Usual Care individualQ G#39#&T5:MX%3(,:23#12%(+4554"%+Q 7&2C(64+,*2(,%394$(64+($%3%+,#&#&-(#&$#"#$:*2 3+%*3,%&3(%Y%3#"%&%55Q ?+4M2%,5/(4,12#*3%$(34(5%3(:1<(*&*2C5#5(#5 $#Z:23<(2#332%(H&4S&<(&43(S#$%2C(:5%$
  6. 6. !"#$%&%(!U3+*3#4&Q !"#$%&%(#5(54,%39#&-(34(M%(%U3+*3%$ 6+4,(39%(*+%(1+4%55 [ ,#&#&-(#3(6+4,(39%($*3* [ $#+%32C(,*&#1:2*3#&-(39%(*+%(1+4%55(S#39 +#-#$(*&$(1+%T$%R&%$(1+434425
  7. 7. !"#$%&%(;3+#1(=#&#&-
  8. 8. !"#$%&%()*+,#&- Hay, et al. J Eval Clin Prac 14(2008):707-713.
  9. 9. I443#&-(64+(!"#$%&%
  10. 10. 0&$:53+#*2(!"#$%&%()*+,#&- Asthma App ER visits at 1 year 50 people100 people Usual Care ER visits at 1 year 50 people population
  11. 11. ?%+54&*2(!"#$%&%(*+$%&5 Asthma app Usual Care Asthma app peak flow peak flow Usual Care Asthma app Usual Care individual
  12. 12. ?%+54&*2(!"#$%&%(*+$%&5 Flovent Flovent PRN Flovent dancing dancing Flovent PRN Flovent Flovent PRN individual
  13. 13. @+4S$54:+#&-(G9*3(=*33%+5Q V@4,12%U%5(46W(!U145:+%5 [ $4%5(9442*3%(3+#--%+(V,CW(*539,*O [ 3%53#&-(4,,4&(+%-#,%&5(V8@!0<(53*3#&<(MTM24H%+W< 4,12%,%&3*+C(,%$##&%5Q V@4,12%U%5(46W(7:34,%5 [ S9*3(4:34,%5($4(1*3#%&35(*+%(*M4:3O
  14. 14. !"#$%&%(=*+45C53%,Rooting for Industrial Evidence Personal Evidence Evidence Farming Gardens
  15. 15. ]4S(*&(S%(5*2%(%"*2:*3#4&O
  16. 16. ;34"%1#1%$ ,]%*239Q ]%*239(*115(M:#23 #&$%1%&$%&32C [ 2#332%($*3*(59*+#&-(*&$ #&3%+41%+*M#2#3CQ ^#,#35(%Z#%&C(*&$ #,1*3(46(_:*2#3C ,]%*239
  17. 17. 0&3%+&%3(]4:+-2*55(=4$%2Q ;3*&$*+$#K%(*&$ ,*H%(41%&(39% N&*++4S(S*#53PQ I%$:%5($:12#*3#4&< 51:+5(4,,:&#3C #&&4"*3#4&<(5:114+35 4,,%+#*2(*&$(&4&T 1+4R3(:5%5
  18. 18. 71%&,]%*239`4+- Estrin DE, Sim I. Science; 330: 759-60. 2010.
  19. 19. 71%&,]%*239`4+-Q A9%(S*#53(594:2$(5:114+3 39%(%"#$%&%(,*+45C53%,
  20. 20. 71%&(8+9#3%3:+%(64+(*& !"#$%&%(=*+45C53%,Q =4$:2%5(64+(:5*-%(*&*2C3#5 [ a(46(3%U3(,%55*-%5<(a(46(5%55#4&5<(%3`Q I443#&-(64+(V-24*2W(%"#$%&% [ $*3*(59*+#&-(S#39(59*+%$(5C&3*U(*&$(5%,*&3#5Q 0&$:53+#*2(6*+,#&-<(%`-`<(S#39(I@A5 [ ,4$:2%5(64+(#&64+,%$(4&5%&3<(+*&$4,#K*3#4&<(*$*13#"% 3+%*3,%&3(53+*3%-C<(,#U%$(,%394$5<(%3`Q ?%+54&*2(%"#$%&%(-*+$%&#&-<(%`-`<(LT46T. [ ,4$:2%5(64+(5+#13#&-(*&$(*&*2CK#&-(#&$#"#$:*2#K%$(LT46T .(1+434425<(%3`
  21. 21. 71%&(8+9#3%3:+%(64+(*& !"#$%&%(=*+45C53%,Q ;4#*2(,%$#*(64+($#54"%+C(46(%U145:+%5(*&$ 4:34,%5(39*3(,*33%+Q ;9*+%$(2#M+*+#%5(46("*2#$*3%$(,%*5:+%5(*&$ #&53+:,%&35(V%`-`<(?I7=0;W [ ,%*5:+%5(39*3(-%3(*3(R&%+T-+*#&%$(,%9*&#5,5(M*5%$ 4&(39%4+%3#*2(,4$%25(46(9*&-%<(%3`
  22. 22. 4*2(64+(,]%*239(!"#$%&%Q 8(2%*+&#&-(4,,:&#3C(4:12%$(S#39(*& 41%&(*+9#3%3:+%(64+(M+4*$<(+*1#$<(*&$ #3%+*3#"%($#55%,#&*3#4&(46(%"*2:*3#4& ,%394$5(*&$(R&$#&-5(39*3(,*33%+
  23. 23. Q 0$*(;#,(#$*`5#,b:56`%$:Q >%M4+*9(!53+#&($%53+#&b5`:2*`%$:Q 9331/cc41%&,9%*239`4+-c

×